Ruijian Pharmaceuticals completes a 260 million yuan Series C funding.

On July 2nd, Ruijian Pharmaceuticals announced the completion of a 260 million yuan C+ round of financing. This round of financing was led by Chengdu Science and Technology Innovation Investment, with participation from CITIC Securities Investment, Xi Venture Capital, Dingtai Xing, Xinjiye, and Hongyi Capital, among others. Existing shareholders Yuan Xihaihe, Jinsha River Joint Runpu Garden also increased their investment. With the completion of this round of financing, Ruijian Pharmaceuticals introduced Tim Ruan, an international capital market executive, to oversee the company's future capital operations. Ruan Tianshi previously served as an executive director at Goldman Sachs and vice president at Morgan Stanley.